Cite
Topp MS, Göckbuget N, Stein AS. Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol. 2015;16(4):e158doi: 10.1016/S1470-2045(15)70154-3.
Topp, M. S., Göckbuget, N., & Stein, A. S. (2015). Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. The Lancet. Oncology, 16(4), e158. https://doi.org/10.1016/S1470-2045(15)70154-3
Topp, M S, et al. "Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study." The Lancet. Oncology vol. 16,4 (2015): e158. doi: https://doi.org/10.1016/S1470-2045(15)70154-3
Topp MS, Göckbuget N, Stein AS. Correction to Lancet Oncol 2015; 16: 60, 61. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multi-centre, single-arm, phase 2 study. Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70154-3. PMID: 25846094.
Copy
Download .nbib